Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Global Blood Therapeutics, Inc. - Common Stock
(NQ:
GBT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 4, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Global Blood Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report
↗
August 05, 2022
Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline.
Via
Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
↗
August 05, 2022
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 04, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
August 04, 2022
Via
Benzinga
Recap: Global Blood Therapeutics Q1 Earnings
↗
May 04, 2022
Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
↗
August 05, 2022
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...
Via
Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
↗
August 04, 2022
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
Via
Benzinga
Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
↗
August 04, 2022
Via
Benzinga
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
↗
August 04, 2022
Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday.
Via
Benzinga
Why Global Blood Therapeutics Stock Is Surging After Hours
↗
August 03, 2022
Global Blood Therapeutics Inc (NASDAQ: GBT) shares are soaring in Wednesday's after-hours session following a report suggesting the company is attracting takeover interest.
Via
Benzinga
7 Small-Cap Growth Stocks With 1,000% Upside Potential
↗
July 31, 2022
Here're 7 small-cap growth stocks with 1,000% upside potential. ACLS, AXSM, GBT, GPRO, HCAT, SKLZ, and VERU can make great investments.
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
↗
July 26, 2022
Via
Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
↗
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
↗
July 06, 2022
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.
Via
Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
↗
July 05, 2022
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.
Via
Investor's Business Daily
Looking Into Global Blood Therapeutics's Return On Capital Employed
↗
June 28, 2022
According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of...
Via
Benzinga
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
↗
June 10, 2022
The company is using a different approach to tackle the blood disease.
Via
Investor's Business Daily
7 No-Brainer Biotech Stocks to Add to Your Buy List
↗
June 09, 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.
Via
InvestorPlace
Global Blood Therapeutics Earnings Perspective: Return On Capital Employed
↗
May 20, 2022
According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42...
Via
Benzinga
Looking Into Global Blood Therapeutics's Return On Capital Employed
↗
April 26, 2022
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Global Blood Therapeutics
↗
February 28, 2022
Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Recap: Global Blood Therapeutics Q4 Earnings
↗
February 23, 2022
Global Blood Therapeutics (NASDAQ:GBT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement...
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
↗
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
↗
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
↗
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
↗
February 02, 2022
Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.
Via
Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
↗
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years
↗
December 20, 2021
The FDA has granted accelerated approval to Global Blood Therapeutics Inc's (NASDAQ: GBT) supplemental application seeking approval for Oxbryta (voxelotor...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
December 17, 2021
Gainers GBS (NASDAQ:GBS
Via
Benzinga
Global Blood Raises $300M Via Convertible Debt Offering
↗
December 15, 2021
Global Blood Therapeutics Inc (NASDAQ: GBT) priced $300 million Convertible Senior Notes due 2028 in a private offering. The offering size was increased from...
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
